Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Dive into Margaret Atwood's The Handmaid's Tale, a work that confronts you with a world where women fight for their freedom.

The Mount Gilead cross country boys picked up a team title Tuesday at the Upper Sandusky Icebreaker Invitational. The team scored 27 points to top the 14-team field. Columbus Grove was second with 48.

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

At a Television Critics Association panel on Jan 14., show creator Bruce Miller revealed that the writers foresaw Trump's ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

The Handmaid's Tale got people talking right from the start. The show began in 2017 and threw us into Gilead, a scary place where women lose their rights and their names.

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...